William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Commentary|Videos|May 30, 2026
Rana McKay, MD, on radium-223 plus cabozantinib in renal cell carcinoma
Author(s)Rana R. McKay, MD
Fact checked by: Hannah Clarke, Tracy Ann Politowicz
Rana R. McKay, MD, FASCO, highlights phase 2 data on radium-223 dichloride plus cabozantinib for patients with renal cell carcinoma with bone metastases.
Advertisement
In the following interview, conducted at the
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5